Interleukin-17 could promote breast cancer progression at several stages of the disease

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Welte, Thomas ^a,b   Zhang, Xiang H F ^b  

^a Diana Helis Henry Medical Research Foundation   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; IL17A PROTEIN, HUMAN;

ANGIOGENESIS; BONE DESTRUCTION; BONE MARROW CELL; BREAST CANCER; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER PATIENT; CARCINOGENESIS; CELL INVASION; CELL SURVIVAL; CYTOKINE RESPONSE; HUMAN; IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TUMOR ESCAPE; TUMOR INVASION; TUMOR VASCULARIZATION; BREAST NEOPLASMS; CANCER STAGING; DISEASE COURSE; FEMALE; IMMUNOLOGY; METASTASIS; PATHOLOGY; PHYSIOLOGY;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-17; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOVASCULARIZATION, PHYSIOLOGIC; TUMOR ESCAPE;

EID: 84953923604     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/804347     Document Type: Review

References (49)

1. Y. Iwakura, H. Ishigame, S. Saijo, and S. Nakae, "Functional specialization of interleukin-17 familymembers," Immunity, vol. 34, no. 2, pp. 149-162, 2011.
2. J. P. Mcaleer and J. K. Kolls, "Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense," Immunological Reviews, vol. 260, no. 1, pp. 129-144, 2014.
3. Z. Yao, W. C. Fanslow, M. F. Seldin et al., "Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor," Immunity, vol. 3, no. 6, pp. 811-821, 1995.
4. P. Miossec, T. Korn, and V. K. Kuchroo, "Interleukin-17 and type helper T cells,"The New England Journal ofMedicine, vol. 361, no. 9, pp. 848-898, 2009.
5. C. L. Roark, J. D. French, M. A. Taylor, A. M. Bendele, W. K. Born, and R. L. OBrien, "Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells," The Journal of Immunology, vol. 179, no. 8, pp. 5576-5583, 2007.
6. Y. Lin, S. Ritchea, A. Logar et al., "Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis," Immunity, vol. 31, no. 5, pp. 799-810, 2009.
7. X. O. Yang, S. H. Chang, H. Park et al., "Regulation of inflammatory responses by IL-17F," Journal of Experimental Medicine, vol. 205, no. 5, pp. 1063-1075, 2008.
8. S. B. Forlow, J. R. Schurr, J. K. Kolls, G. J. Bagby, P. O. Schwarzenberger, and K. Ley, "Increased granulopoiesis through interleukin-17 and granulocyte colony-stimulating factor in leukocyte adhesion molecule-deficient mice," Blood, vol. 98, no. 12, pp. 3309-3314, 2001.
9. P. Ye, P. B. Garvey, P. Zhang et al., "Interleukin-17 and lung host defense against klebsiella pneumoniae infection," American Journal of Respiratory Cell and Molecular Biology, vol. 25, no. 3, pp. 335-340, 2001.
10. R. Gopal, Y. Lin, N. Obermajer et al., "IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination," European Journal of Immunology, vol. 42, no. 2, pp. 364-373, 2012.
11. S. A. Khader and R. Gopal, "IL-17 in protective immunity to intracellular pathogens," Virulence, vol. 1, no. 5, pp. 423-427, 2010.
12. X. Su, J. Ye, E. C. Hsueh, Y. Zhang, D. F. Hoft, and G. Peng, "Tumor microenvironments direct the recruitment and expansion of humanTh17 cells,"TheJournal of Immunology, vol. 184, no. 3, pp. 1630-1641, 2010.
13. S. Cochaud, J. Giustiniani, C. Thomas et al., "IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2," Scientific Reports, vol. 3, article 3456, 2013.
14. W.-C. Chen, Y.-H. Lai, H.-Y. Chen, H.-R. Guo, I.-J. Su, and H. H. W. Chen, "Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor," Histopathology, vol. 63, no. 2, pp. 225-233, 2013.
15. L. Wang, Y. Jiang, Y. Zhang et al., "Association analysis of IL-17A and IL-17F polymorphisms in Chinese Hanwomen with breast cancer," PLoS ONE, vol. 7, no. 3, Article ID e34400, 2012.
16. L. Benevides, C. R. B. Cardoso, D. G. Tiezzi, H. R. C. Marana, J. M. Andrade, and J. S. Silva, "Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor," European Journal of Immunology, vol. 43, no. 6, pp. 1518-1528, 2013.
17. L. Benevides, D. M. da Fonseca, P. B. Donate et al., "IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment," Cancer Research, vol. 75, no. 18, pp. 3788-3799, 2015.
18. C. Horlock, B. Stott, P. J. Dyson et al., "The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ Tcell axis in patients with breast cancer," British Journal of Cancer, vol. 100, no. 7, pp. 1061-1067, 2009.
19. S. Mombelli, S. Cochaud, Y. Merrouche et al., "IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells," Scientific Reports, vol. 5, Article ID 11874, 2015.
20. S. Furuta, Y.-M. Jeng, L. Zhou et al., "IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells," Science Translational Medicine, vol. 3, no. 78, Article ID 78ra31, 2011.
21. V. Younesi and F. Nejatollahi, "Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells," International Immunopharmacology, vol. 23, no. 2, pp. 624-632, 2014.
22. T. Benatar, M. Y. Cao, Y. Lee et al., "Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors," Cancer Immunology, Immunotherapy, vol. 57, no. 12, pp. 1757-1769, 2008.
23. T. Benatar, M. Y. Cao, Y. Lee et al., "IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo," Cancer Immunology, Immunotherapy, vol. 59, no. 6, pp. 805-817, 2010.
24. C.-K. Huang, C.-Y. Yang, Y.-M. Jeng et al., "Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-kappaB-mediated antiapoptotic pathway," Oncogene, vol. 33, no. 23, pp. 2968-2977, 2014.
25. X.-J. Ma, Z. Wang, P. D. Ryan et al., "Atwo-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen," Cancer Cell, vol. 5, no. 6, pp. 607-616, 2004.
26. J.-S. Nam, M. Terabe, M.-J. Kang et al., "Transforming growth factor beta subverts the immune systeminto directly promoting tumor growth through interleukin-17," Cancer Research, vol. 68, no. 10, pp. 3915-3923, 2008.
27. A. N. Jewell, M. Swamydas, C. I. Castillo et al., "The endothelin axis stimulates the expression of pro-inflammatory cytokines and pro-migratory molecules in breast cancer," Cancer Investigation, vol. 28, no. 9, pp. 932-943, 2010.
28. G. Kim, P. Khanal, S.-C. Lim et al., "Interleukin-17 induces AP-activity and cellular transformation via upregulation of tumor progression locus 2 activity," Carcinogenesis, vol. 34, no. 2, pp. 341-350, 2013.
29. H. Kim, Y. Kim, S. Bae et al., "Direct interaction of CD40 on tumor cells with CD40L on T cells increases the proliferation of tumor cells by enhancing TGF-β production and Th17 differentiation," PLoS ONE, vol. 10, no. 5, Article ID e0125742, 2015.
30. X. Zhu, L. A. Mulcahy, R. A. A. Mohammed et al., "IL-17 expression by breast-cancer-associatedmacrophages: IL-17 promotes invasiveness of breast cancer cell lines," Breast Cancer Research, vol. 10, no. 6, article R95, 2008.
31. A. S. Chung, X. Wu, G. Zhuang et al., "An interleukin-17-mediated paracrine network promotes tumor resistance to antiangiogenic therapy," Nature Medicine, vol. 19, no. 9, pp. 1114-1123, 2013.
32. G. Bian and W.-Y. Zhao, "IL-17, an important prognostic factor and potential therapeutic target for breast cancer?" European Journal of Immunology, vol. 44, no. 2, pp. 604-605, 2014.
33. J.-W. Du, K.-Y. Xu, L.-Y. Fang, and X.-L. Qi, "Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer," Molecular Medicine Reports, vol. 6, no. 5, pp. 1099-1102, 2012.
34. T. Freire, R. Lo-Man, S. Bay, and C. Leclerc, "Tn glycosylation of theMUC6proteinmodulates itsimmunogenicity and promotes the induction of Th17-biased T cell responses," The Journal of Biological Chemistry, vol. 286, no. 10, pp. 7797-7811, 2011.
35. S. V. Novitskiy, M. W. Pickup, A. E. Gorska et al., "TGF-β receptor II loss promotes mammary carcinoma progression by Th17-dependent mechanisms," Cancer Discovery, vol. 1, no. 5, pp. 430-441, 2011.
36. S. B. Coffelt, K. Kersten, C. W. Doornebal et al., "IL-17-producing γΔ T cells and neutrophils conspire to promote breast cancer metastasis," Nature, vol. 522, no. 7556, pp. 345-348, 2015.
37. T. Welte, J. Aronson, B. Gong et al., "Vγ4+ T cells regulate host immune response to West Nile virus infection," FEMS Immunology and Medical Microbiology, vol. 63, no. 2, pp. 183-192, 2011.
38. B. Martin, K. Hirota, D. J. Cua, B. Stockinger, and M. Veldhoen, "Interleukin-17-producing γΔ T cells selectively expand in response to pathogen products and environmental signals," Immunity, vol. 31, no. 2, pp. 321-330, 2009.
39. N. Eiro, L. Gonzalez, L. O. Gonzalez et al., "Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development," PLoS ONE, vol. 7, no. 11, Article ID e49047, 2012.
40. N. Eiro, B. Fernandez-Garcia, L. O. Gonzalez, and F. J. Vizoso, "Cytokines related to MMP-11 expression by inflammatory cells and breast cancer metastasis," OncoImmunology, vol. 2, no. 5, Article ID e24010, 2013.
41. R. H. Goldstein, M. R. Reagan, K. Anderson, D. L. Kaplan, and M. Rosenblatt, "Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis," Cancer Research, vol. 70, no. 24, pp. 10044-10050, 2010.
42. L. Das Roy, L. B. Pathangey, T. L. Tinder, J. L. Schettini, H. E. Gruber, and P. Mukherjee, "Breast-cancer-associatedmetastasis is significantly increased in a model of autoimmune arthritis," Breast Cancer Research, vol. 11, no. 4, article R56, 2009.
43. L. D. Roy, S. Ghosh, L. B. Pathangey, T. L. Tinder, H. E. Gruber, and P. Mukherjee, "Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer," BMC Cancer, vol. 11, article 365, 2011.
44. L. D. Roy, M. Sahraei, J. L. Schettini, H. E. Gruber, D. M. Besmer, and P. Mukherjee, "Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches," BMC Cancer, vol. 14, article 225, 2014.
45. J. N. Ingle, "Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations," Breast Cancer Research, vol. 12, supplement 4, article S17, 2010.
46. J. N. Ingle, D. J. Schaid, P. E. Goss et al., "Genome-wide associations and functional genomic studies ofmusculoskeletal adverse events in women receiving aromatase inhibitors," Journal of Clinical Oncology, vol. 28, no. 31, pp. 4674-4682, 2010.
47. M. Liu, L. Wang, T. Bongartz et al., "Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression," Breast Cancer Research, vol. 14, no. 2, article R41, 2012.
48. Y. Ma, L. Aymeric, C. Locher et al., "Contribution of IL-17-producing γΔ Tcells to the efficacy of anticancer chemotherapy," The Journal of Experimental Medicine, vol. 208, no. 3, pp. 491-503, 2011.
49. S. R. Mattarollo, S. Loi, H. Duret, Y. Ma, L. Zitvogel, and M. J. Smyth, "Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors," Cancer Research, vol. 71, no. 14, pp. 4809-4820, 2011.